Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)
The one trial still testing an antibody-drug conjugate in mesothelioma, combining it with PD-1 blockade on the theory that payload-induced cell death primes an immune response.
Overview
This National Cancer Institute study enrolled 49 patients with mesothelin-positive pleural mesothelioma after prior therapy. A phase 1 run-in established the dose of anetumab ravtansine with pembrolizumab, and the phase 2 part randomised patients to pembrolizumab with or without the conjugate. The study is active but no longer recruiting, with results awaited. It is the only remaining clinical test of an ADC in mesothelioma recorded on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialAnetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma
Shares Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work, Anetumab ravtansine, Mesothelin, Mesothelioma and the tag owner-request.
- TrialHemithoracic irradiation with proton therapy in malignant pleural mesothelioma (UCL)
Shares Mesothelioma and the tag owner-request.
- TrialCemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)
Shares Immune checkpoint inhibitors and the tag owner-request.
- TrialZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1)
Shares National Cancer Institute (NIH) and the tag owner-request.
- TrialZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2)
Shares National Cancer Institute (NIH) and the tag owner-request.
- PersonRaffit Hassan
Shares Mesothelin, Mesothelioma, National Cancer Institute (NIH).
- TreatmentEB-MF-CAR-NK-01
Shares Mesothelin, Mesothelioma.
- IdeaTreat the body cavity, not the bloodstream, for surface spread
Shares Mesothelin, Mesothelioma, Immune checkpoint inhibitors.